TABLE 2.
Results for Lasmiditan, Rimegepant, Ubrogepant, and Sumatriptan and Eletriptan for Triptan-Eligible Population
| Treatment | Total Cost | QALY | Hours of Pain | New Interventions Versus Sumatriptan | New Interventions Versus Eletriptan | ||
|---|---|---|---|---|---|---|---|
| Cost per QALY | Cost per Hour of Pain Avoided | Cost per QALY | Cost per Hour of Pain Avoided | ||||
| Lasmiditan | $12,000 | 1.8271 | 1,650 | Dominated | Dominated | Dominated | Dominated |
| Ubrogepant | $13,020 | 1.8221 | 1,876 | Dominated | Dominated | Dominated | Dominated |
| Rimegepant | $13,010 | 1.8222 | 1,870 | Dominated | Dominated | Dominated | Dominated |
| Sumatriptan | $6,630 | 1.8264 | 1,610 | comparator | comparator | - | - |
| Eletriptan | $6,790 | 1.8293 | 1,480 | - | - | comparator | comparator |
QALY = quality-adjusted life-years.